tranexamic acid has been researched along with Heart Valve Diseases in 5 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons." | 5.36 | Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010) |
| "Tranexamic acid was as effective and as safe as high dose aprotinin." | 2.68 | [Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin]. ( Benmosbah, L; Boughenou, F; Carpentier, A; Cousin, MT; Madi-Jebara, S; Massonnet-Castel, S, 1995) |
| "The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons." | 1.36 | Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010) |
| "Glanzmann thrombasthenia is a rare congenital platelet disorder characterized by spontaneous mucocutaneous bleeding and severe bleeding complications during major surgery." | 1.35 | Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery. ( Heindl, B; Lison, S; Spannagl, M, 2009) |
| "The tranexamic acid group has received 30 mg kg-1 the acid tranexamic and the aprotinin group has received a low regimen as 500,000 UIK of aprotinin." | 1.32 | [Tranexamic acid versus aprotinin for the prevention of bleeding during mitral valve surgery ]. ( Ait Houssa, M; Amahzoune, B; Arji, M; Azendour, H; Boulahya, A; Elbekkali, Y; Elkirat, A; Ibbat, D; Jabrani, K; Mamoun, F; Selkane, C; Wahid, FA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lison, S | 1 |
| Spannagl, M | 1 |
| Heindl, B | 1 |
| Bell, D | 1 |
| Marasco, S | 1 |
| Almeida, A | 1 |
| Rowland, M | 1 |
| Ait Houssa, M | 1 |
| Boulahya, A | 1 |
| Wahid, FA | 1 |
| Elbekkali, Y | 1 |
| Amahzoune, B | 1 |
| Selkane, C | 1 |
| Elkirat, A | 1 |
| Jabrani, K | 1 |
| Ibbat, D | 1 |
| Azendour, H | 1 |
| Mamoun, F | 1 |
| Arji, M | 1 |
| Boughenou, F | 1 |
| Madi-Jebara, S | 1 |
| Massonnet-Castel, S | 1 |
| Benmosbah, L | 1 |
| Carpentier, A | 1 |
| Cousin, MT | 1 |
| Souto, JC | 1 |
| Oliver, A | 1 |
| Zuazu-Jausoro, I | 1 |
| Vives, A | 1 |
| Fontcuberta, J | 1 |
2 trials available for tranexamic acid and Heart Valve Diseases
| Article | Year |
|---|---|
[Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin].
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Dose-Response Relationship, Drug; D | 1995 |
Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Chi-Square Distributio | 1996 |
3 other studies available for tranexamic acid and Heart Valve Diseases
| Article | Year |
|---|---|
Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion, Au | 2009 |
Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cohort Studies; Coron | 2010 |
[Tranexamic acid versus aprotinin for the prevention of bleeding during mitral valve surgery ].
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiopulmonary Bypass; Dose-Respon | 2003 |